0000358654
Donate

Reimbursement status:
Full reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01BB
L01BB Purine analogues
EMA approval status :
Approved
EMA approval date :
2007-08-22
EMA conditional? :
No
EMA orphan? :
Yes
EMA biological? :
No